> 首页 > 产品 > 一抗 > 其他 > Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab)

Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab)

Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab) is 97.11%, determined by SEC-HPLC.
Erfonrilimab bound to CTLA4 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Erfonrilimab bound in human CTLA4 Protein-His, and the EC50 was 0.010 nM.
Erfonrilimab bound to PD-L1 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Erfonrilimab bound in human PD-L1 Protein-His, and the EC50 was 0.012 nM.
Erfonrilimab bound to huCTLA4-CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Erfonrilimab bound to huCTLA4-CHO-K cells, and the EC50 was 14.510 nM.
Erfonrilimab bound to huPD-L1-CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Erfonrilimab bound to huPD-L1-CHO-K cells, and the EC50 was 1.759 nM.
Co-incubation of Erfonrilimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Erfonrilimab was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 0.681 nM.
The detected molecular weight of Anti-CTLA4 & PD-L1 Reference Antibody (Erfonrilimab) is 107.14 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P16410 & Q9NZQ7
Reactivity	Human
Clonality	Bispecific
Isotype	VHH-VHH-Fc

Additional Information
Target/Specificity	CTLA-4 / CD152,B7-H1 / PD-L1 / CD274
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.